![](https://www.webhealthnetwork.com/img/webhealth-logo.png)
Focal Segmental Glomerulosclerosis - 27 Studies Found
Terminated |
: Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS) : Focal Segmental Glomerulosclerosis : 2008-10-27 : Drug: FG-3019 FG-3019 5 mg/kg IV given over 2 hours every 2 weeks for 8 weeks |
Terminated |
: Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis : Focal Segmental Glomerulosclerosis : 2009-08-10 :
|
Completed |
: Permeability Factor in Focal Segmental Glomerulosclerosis : Focal Segmental Glomerulosclerosis : 2000-12-22 :
|
Terminated |
: Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor : Focal Segmental Glomerulosclerosis : 2008-12-31 : Drug: Galactose Oral galactose, 0.2 g/kg/dose twice daily for 28 days |
Recruiting |
: Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis) : Focal Segmental Glomerulosclerosis : 2015-03-03 : Biological: Intravenous injection Intravenous injection of AD-MSC to the patients with FSGS |
Active, not recruiting |
: Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis : Focal Segmental Glomerulosclerosis : 2012-06-04 :
|
Completed |
: Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS : Focal Segmental Glomerulosclerosis : 2007-04-20 :
|
Completed |
: Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT) : Glomerulosclerosis, Focal : 2005-08-24 :
|
Recruiting |
: Genetic Markers for Focal Segmental Glomerulosclerosis :
|